Overview

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Status:
Not yet recruiting
Trial end date:
2025-11-15
Target enrollment:
Participant gender:
Summary
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, Irvine
Treatments:
Acetylcysteine
N-monoacetylcystine